Research
staff at the UK's University of Nottingham are currently working on
the creation of a new way to tackle cancer
They're developing a double action vaccine,
designed to attack both the tumour cells and the blood vessels
feeding the tumour.
This unique vaccine is already halfway
there. A vaccine called 105AD7 has now been used to treat over 300
patients by stimulating their immune cells to recognise and kill
their own tumour cells.
Now research is centred on developing a
vaccine that kills the blood cells feeding a tumour. For a tumour
to grow it needs a good blood supply - cutting this supply could
lead to the death of thousands of tumour cells.
Currently the vaccine targeting the blood
vessels works well in model systems in the lab and will hopefully
enter clinical trials in the next year. It can then be tested in
combination with 105AD7.
It's too early to say how successful this
new double-attack vaccine will be. It's a painstaking process of
trial and error - but if the hard work of Nottingham's Research
Team pays off there'll be a new "magic bullet" in the
battle against cancer.
Research
staff at the UK's University of Nottingham are currently working on
the creation of a new way to tackle cancer